Furthermore, as ICIs targeting the PD-1 pathway are designed to reduce immune tolerance and reverse T-cell exhaustion in malignancies, the loss of inhibitory signals transmitted through these pathways may shift the balance toward T-cell-mediated inflammation and disruption of self-tolerance (31). This evidence concerns the gene PDCD1 and cancer.